Monkeypox: WHO Advises Antiviral Use In Trials Or Expanded Access Programs

With more than 1,200 confirmed cases of monkeypox in 28 non-endemic countries and disease incidence also rising in Africa, the WHO and the US CDC have each updated their guidance on the use of antiviral products. The US has just ordered 500,000 more doses of Bavarian Nordic's smallpox vaccine, Jynneos.

Tecovirimat and Brincidofovir, antiviral drugs 3d rendering medical illustration. Both are studied for use on monkeypox virus infections, indicated for smallpox.
Tecovirimat and brincidofovir may be used for severe monkeypox • Source: Shutterstock

Antivirals such as SIGA Technologies, Inc's tecovirimat, Chimerix, Inc.'s brincidofovir (Tembexa) and generic cidofovir can be used in cases of severe monkeypox disease, preferably in the context of randomized clinical trials with the collection of standardized clinical and outcomes data to quickly generate safety and efficacy data, the World Health Organization advises in its latest guidance.

If clinical trials are not possible, antivirals may be used under expanded access protocols such as MEURI (monitored emergency use...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from International

More from Geography